Cefaly Technology SPRL, a Liège, Belgium-based manufacturer and marketer of neuro-modulating medical devices for the prevention and treatment of migraines, received a majority investment from DW Healthcare Partners, a healthcare-focused private equity firm.
This is the first investment of DW Healthcare Partners V, L.P., the firm’s recently closed, $610m fifth fund.
The company will use the proceeds from the investment to enter its next stage of growth.
Founded in 2004 by Dr. Pierre Rigaux and Pierre-Yves Muller, Cefaly provides a device externally applied by the patient to the forehead to deliver electrical impulses to the trigeminal nerve, a critical component of the nervous system involved in almost all migraines. The device is registered with the FDA, CE mark certified, and with many years of active commercial use.
Concurrent with the closing, Jen Trainor joined Cefaly as Chief Executive Officer. Trainor is an accomplished executive with domestic and international experience in marketing, sales, operations and multichannel product distribution.
Most recently, she was President of a global health and wellness brand at The Nature’s Bounty Company.